Recent Posts
The IN VIVO Blog
Return To Blog Listing
News, insight and analysis on the business of the biopharmaceutical industry from the editors of Windhover Information and FDC Reports, publishers of IN VIVO and "The Pink Sheet".
Recent Posts Tagged With 'oncology'
Deals of the Week: Merry Chrismahanukwanzakah
It's that time of year. Time for making merry with wassail, carbohydrates, and Tiny Tim-isms. In the spirit of inclusion, it's tempting to spit "Bah, Humbug," but Joe Lieberman beat us to it.Perhaps three ghosts will haunt the Connecticut Senator in ...
He Said, He Said
It’s not unusual for a financial analyst and a biopharmaceutical CEO to disagree about the value of a particular program or molecule. But when a CEO accuses an analyst of not having done his homework, it’s a different matter. But that’s precise...
2009 M&A/Alliances DOTY Nominee: Astellas/Medivation
It's time for the IN VIVO Blog's Second Annual Deal of the Year! competition. This year we're presenting awards in three categories--that's 300% more fake prizes than last year!--to highlight the most interesting and creative deal making solutions of...
DotW: You Can Get Anything You Want At IN VIVO Blog
This post is called Deals of the Week, and it's about deals, and the week, but Deals of the Week is not the name of the blog, that's just the name of the post. And that's why I called the post Deals of the Week.You can get anything you want at IN VIV...
How Close Avastin Really Came To Adjuvant Colorectal Cancer Use
Six events. Six additional cases of recurrence out of the 2,710 patients being treated in the C-08 trial of Roche/Genentech’s Avastin in adjuvant colorectal cancer, and there would have been an entirely different outcome.Six more cases at the inter...
ASCO Postscript: In Oncology, Cost is in the Hot Seat
This past ASCO meeting may have held few surprises on clinical data, but it certainly brought cost pressures to the forefront of oncology. The message: cost now matters in oncology treatment, just as it does in the rest of the pharma industry.Oncolog...
Saving Money on Volume: Obama Advisor Talks Cost Control With ASCO
Sometimes less is more. At least where healthcare reform and oncology are concerned, bringing volume down is the best path to reducing healthcare costs, according to Obama administration health advisor Ezekiel Emanuel.Emanuel--an oncologist, a senior...
While You Were at ASCO
Hey you'll never guess, but there was an oncology meeting down in Mickey-Mouse land this weekend. No, seriously. Small group of cancer docs, it flies below the radar. Yeah that's probably why you hadn't heard of it. Say it with us: Aaasssssccccoooooo...
Merck/AZ Cancer Deal: Will Intra-Big Pharma Development Deals Move Beyond the Serendipitous?
Is that a mek inhibitor, sir?Merck and AstraZeneca are expected to announce today that they're teaming up to test a combination of two early-stage oncology candidates. The companies are billing the deal as a first-of-its-kind collaboration--and fair...
Exelixis/Sanofi: The Price of Playing in PI3K
During Exelixis' year-end pipeline update in December 2008, following the biotech's lucrative XL184 et al. deal with BMS, Exelixis R&D chief Michael Morrissey said that the company's two PI3 kinase programs, XL147 and XL765, would likely be out-l...
JNJ Likes it Some Cougar. Rwwwaaarrrr!
Last night (alas, not at "midnight" like the Cougar in the above ad--email subscribers if you can't see the ad [you want to, it's a classic] click here.) Johnson & Johnson bought Cougar Biotechnology for $43/share in cash, or approximately a cool...
Notes From BIO: The Pathology of Personalized Medicine
Translating the vision of personalized medicine into reality is no simple matter, but here's an obstacle we hadn't considered before: the need to update the 19th century science of tumor pathology to address 21st century demands for biomarkers.Pathol...
